MedPath

To compare the efficacy of Nitazoxanide in a single dose of 3g VO and metronidazole in a single dose of 2g in the eradication of T. vaginalis.

Not Applicable
Conditions
-A59 Trichomoniasis
Trichomoniasis
A59
Registration Number
PER-009-02
Lead Sponsor
ASOCIACION BENEFICA PRISMA,
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

• Patients 18 years of age or older, with vaginal discharge.
• Presence of mobile trichomonads in direct examination with saline or culture Positive to T. vaginalis or Polymerase Chain Reaction Test (PCR) positive for T. vaginalis in the 5 days prior to inclusion in the study.
• Written informed consent of the patient or her legal representative.
• Patients of reproductive age must also have a pregnancy test in negative urine in the 48 hours prior to the start of the clinical study.

Exclusion Criteria

• Diagnosis of Vulvovaginal Candidiasis by identification of pseudohyphae in
the direct examination.
• Diagnosis of Bacterial Vaginosis by observation of clue cells in the
direct examination.
• Having received a derivative of S-nitroimidazoIe (metronidazole, tinidazole,
ornidazole or secnidazole) or treatment with nitazoxanide in a period of 14 days
prior to randomization.
• History of hypersensitivity to nitazoxanide or metronidazole.
• Pregnancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath